Albireo Pharma, Inc. – NASDAQ:ALBO
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
Albireo Pharma stock price monthly change
-0.90%
month
Albireo Pharma stock price quarterly change
+85.66%
quarter
Albireo Pharma stock price yearly change
+64.62%
year
Albireo Pharma key metrics
Market Cap | 915.88M |
Enterprise value | N/A |
P/E | -6.62 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | 15.12 |
Price/Book | 8.67 |
PEG ratio | -0.08 |
EPS | -7.04 |
Revenue | 57.39M |
EBITDA | -122.48M |
Income | -137.38M |
Revenue Q/Q | 168.34% |
Revenue Y/Y | 432.68% |
Profit margin | -228.51% |
Oper. margin | -214.16% |
Gross margin | 95.56% |
EBIT margin | -214.16% |
EBITDA margin | -213.42% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAlbireo Pharma stock price history
Albireo Pharma stock forecast
Albireo Pharma financial statements
| Dec 2021 | 32.52M | -10.96M | -33.71% |
|---|---|---|---|
| Mar 2022 | 6.83M | -45.31M | -663.2% |
| Jun 2022 | 8.20M | -42.69M | -520.29% |
| Sep 2022 | 9.83M | -38.41M | -390.69% |
| 2022-08-15 | -1.65 | -2.04 |
|---|---|---|
| 2022-11-08 | -1.06 | -1.92 |
| 2023-03-07 | -1.8 | -0.57 |
| Dec 2021 | 302051000 | 126.44M | 41.86% |
|---|---|---|---|
| Mar 2022 | 261261000 | 113.07M | 43.28% |
| Jun 2022 | 229014000 | 115.33M | 50.36% |
| Sep 2022 | 321222000 | 221.15M | 68.85% |
| Dec 2021 | -13.89M | -279K | 370K |
|---|---|---|---|
| Mar 2022 | -35.40M | -235K | 4.38M |
| Jun 2022 | -36.39M | -685K | 1.80M |
| Sep 2022 | -29.63M | -40K | 121.48M |
Albireo Pharma alternative data
| Aug 2023 | 130 |
|---|---|
| Sep 2023 | 130 |
| Oct 2023 | 130 |
| Nov 2023 | 130 |
| Dec 2023 | 130 |
| Jan 2024 | 130 |
| Feb 2024 | 130 |
| Mar 2024 | 130 |
| Apr 2024 | 130 |
| May 2024 | 130 |
| Jun 2024 | 130 |
| Jul 2024 | 130 |
Albireo Pharma other data
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2022 | 0 | 454 |
| Apr 2022 | 0 | 2270 |
| Jun 2022 | 0 | 461 |
| Jul 2022 | 0 | 2310 |
| Sep 2022 | 0 | 445 |
| Oct 2022 | 0 | 422689 |
| Dec 2022 | 0 | 938 |
| Jan 2023 | 0 | 12196 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | CARTER MARTHA J. officer: Chief Re.. | Common Stock | 120 | $43.8 | $5,256 | ||
Sale | MATTSSON JAN officer: Chief Scientific Officer | Common Stock | 197 | $43.8 | $8,629 | ||
Sale | COOPER RONALD HAROLD WILFRED director, officer.. | Common Stock | 1,057 | $43.8 | $46,297 | ||
Sale | DUNCAN JASON officer: Chief Legal Officer an.. | Common Stock | 228 | $43.8 | $9,986 | ||
Sale | HARFORD SIMON N.R. officer: CFO and Treasurer | Common Stock | 102 | $43.8 | $4,468 | ||
Sale | GRAHAM MICHELLE officer: Chief Human Resources .. | Common Stock | 102 | $43.8 | $4,468 | ||
Sale | STEPHENSON PAMELA officer: Chief Commercial Officer | Common Stock | 102 | $43.8 | $4,468 | ||
Sale | HARFORD SIMON N.R. officer: CFO and Treasurer | Common Stock | 1,776 | $43.8 | $77,789 | ||
Sale | GRAHAM MICHELLE officer: Chief Human Resources .. | Common Stock | 1,774 | $43.9 | $77,886 | ||
Sale | MATTSSON JAN officer: Chief Scientific Officer | Common Stock | 3,088 | $43.8 | $135,254 |
| Quarter | Transcript |
|---|---|
| Q3 2022 8 Nov 2022 | Q3 2022 Earnings Call Transcript |
| Q2 2022 15 Aug 2022 | Q2 2022 Earnings Call Transcript |
| Q1 2022 16 May 2022 | Q1 2022 Earnings Call Transcript |
| Q4 2021 1 Mar 2022 | Q4 2021 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Ronald H. W. Cooper (1963) Chief Executive Officer, Pres & Director | $1,130,000 |
| Ms. Martha J. Carter (1952) Chief Regulatory Officer | $745,730 |
Albireo Pharma: Elucidating The Ipsen Buyout (Rating Upgrade)
Albireo: Strong Phase 3 Data Foretells More Upside
Albireo Pharma: Assessing The Sagard Deal
Mirum: Great Sales Start For Livmarli Paves The Way For Long-Term Growth
Albireo: The Commercialization Of Bylvay Is The Key To A Fair Valuation
Albireo: A Speculative Play With Upside
Adult Liver Diseases: The R&D Engine Drives Albireo's Long-Term Prospects.
Albireo: Successful And Accelerating Global Launch Drives Sales Revenue
Albireo: Reasons For A Successful Transformation Into A Commercial Company
-
When is Albireo Pharma's next earnings date?
Unfortunately, Albireo Pharma's (ALBO) next earnings date is currently unknown.
-
Does Albireo Pharma pay dividends?
No, Albireo Pharma does not pay dividends.
-
How much money does Albireo Pharma make?
Albireo Pharma has a market capitalization of 915.88M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 388.43% to 40.58M US dollars. Albireo Pharma made a loss 151.35M US dollars in net income (profit) last year or -$0.57 on an earnings per share basis.
-
What is Albireo Pharma's stock symbol?
Albireo Pharma, Inc. is traded on the NASDAQ under the ticker symbol "ALBO".
-
What is Albireo Pharma's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Albireo Pharma?
Shares of Albireo Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Albireo Pharma's key executives?
Albireo Pharma's management team includes the following people:
- Mr. Ronald H. W. Cooper Chief Executive Officer, Pres & Director(age: 62, pay: $1,130,000)
- Ms. Martha J. Carter Chief Regulatory Officer(age: 73, pay: $745,730)
-
How many employees does Albireo Pharma have?
As Jul 2024, Albireo Pharma employs 130 workers.
-
When Albireo Pharma went public?
Albireo Pharma, Inc. is publicly traded company for more then 18 years since IPO on 11 May 2007.
-
What is Albireo Pharma's official website?
The official website for Albireo Pharma is albireopharma.com.
-
Where are Albireo Pharma's headquarters?
Albireo Pharma is headquartered at 10 Post Office Square, Boston, MA.
-
How can i contact Albireo Pharma?
Albireo Pharma's mailing address is 10 Post Office Square, Boston, MA and company can be reached via phone at 857 254 5555.
Albireo Pharma company profile:
Albireo Pharma, Inc.
albireopharma.comExchange:
NASDAQ
Full time employees:
130
Industry:
Biotechnology
Sector:
Healthcare
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.
10 Post Office Square
Boston, MA 02109
Boston, MA 02109
CIK: 0001322505
ISIN: US01345P1066
CUSIP: 01345P106
